Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Rocket Pharmaceuticals (NASDAQ:RCKT) with a $62 price target.
June 28, 2024 | 7:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Rocket Pharmaceuticals with a $62 price target.
The reaffirmation of a Buy rating and a $62 price target by Chardan Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100